

In re Application of:

DUMAS, Jacques, et al.

Examiner: KWON, Brian Yong S.

Serial No.: 09/838,286

Group Art Unit: 1614

Filed: 4/20/01

Title: HETEROARYL UREAS CONTAINING NITROGEN HETERO-ATOMS AS P38

KINASE INHIBITORS

RESPONSE TO RESTRICTION REQUIREMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In response to the Restriction Requirement dated October 10, 2003, Applicants hereby elect with traverse Group II (claims 46-74) drawn to a process of treating a disease mediated by p38 kinase inhibitors. The compounds of Group I were searched earlier and should be included in the examined claims of Group II.

Applicants are also required to elect a species (urea and disease state). Applicants elect N-(4-tert-butylpyridinyl)-N1-(4) 4-methoxy phenoxy)phenyl) urea and Rheumatoid arthritis with traverse.

The ureas defined in the method claims 46-74 are specific enough to permit searching of the entire scope of claim 1.

1

No fee is believed to be due with this response, however, the Commissioner is hereby authorized to charge any fees associated with this response or credit any overpayment to Deposit Account No. 13-3402.

Respectfully submitted,

Richard J. Traverso, Reg. No. 30,595 Attorney/Agent for Applicant(s)

MILLEN, WHITE, ZELANO & BRANIGAN, P.C. Arlington Courthouse Plaza 1, Suite 1400 2200 Clarendon Boulevard Arlington, Virginia 22201 Telephone: (703) 243-6333

Facsimile: (703) 243-6410

Attorney Docket No.: BAYER-0014

Date: December 10, 2003